Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study
Hiroshi Onishi, Hiroki Shirato, Yasushi Nagata et al. · Journal of Thoracic Oncology · 2007
Cited by 977 works. doi:10.1097/jto.0b013e318074de34
Authors
- Hiroshi Onishi
- Hiroki Shirato
- Yasushi Nagata
- Masahiro Hiraoka
- Masaharu Fujino
- 光太郎 五味
- Yuzuru Niibe
- Katsuyuki Karasawa
- Kazushige Hayakawa
- Yoshihiro Takai
- Tomoki Kimura
- Atsuya Takeda
- Atsushi Ouchi
- Masato Hareyama
- Masaki Kokubo
- Ryusuke Hara
- Jun Itami
- Kazunari Yamada
- Tsutomu Araki
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma
- Extracranial Stereotactic Radioablation *
- Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience
- Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame
- Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients
- Radiation therapy alone for stage I non-small cell lung cancer
- Stereotactic body radiation therapy of early-stage non–small-cell lung carcinoma: Phase I study
- Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience
- Stereotactic single-dose radiotherapy of stage I non–small-cell lung cancer (NSCLC)